A comparative study of the diagnostic characteristics of the modified RAST and Pharmacia CAP System.

New in vitro technology for the detection of allergen-specific IgE antibody continues to be developed. The manufacturer of one such system, the Pharmacia CAP System, claims that it has test qualities similar to those of the modified RAST. To evaluate this assertion we compared the results obtained with 12 allergens by both procedures on six negative control sera and four sera obtained from atopic patients; a total of 120 tests were performed.

In vitro testing methodologies. Evolution and current status.

Almost 25 years after the development of the radioallergosorbent test, in vitro technology has become firmly established as an outstanding diagnostic tool for physicians treating the allergic patient. The American Academy of Otolaryngic Allergy (AAO), in its most current position statement, endorses the modified RAST as reproducible, sensitive, and specific. A new organization called the American In Vitro Allergy and Immunology Society (AIVAIS) has been formed to promote and monitor the use of these tests.

PRIST, RAST, and beyond. Diagnosis and therapy.

The measurement of total and specific IgE antibody by in vitro methods offers a significant advance in the diagnosis and management of allergic patients. These tests allow the physician to combine a precise diagnosis with an evaluation of patient sensitivity to provide care in a cost-effective manner.